That could lead to more delays, says Hazlett, but right now he expects both Strattera and Cymbalta to receivefinalapproval in the second quarter of 2003.
The FDA will probably follow the panel's recommendation--meaning that a combination of Roche's Pegasys and another drug called Copegus could receivefinal FDA approval by year's end.